Cyslabdan, a New Potentiator of Imipenem Activity against Methicillin-resistant Staphylococcus aureus, Produced by Streptomyces sp. K04-0144

Cyslabdan, a New Potentiator of Imipenem Activity against Methicillin-resistant Staphylococcus aureus, Produced by Streptomyces sp. K04-0144 Biosynthesis of mercapturic acid derivative of the labdane-type diterpene, cyslabdan that potentiates imipenem activity against methicillin-resistant <i>Staphylococcus aureus</i>: cyslabdan is generated by mycothiol-mediated xenobiotic detoxification Krisynomycins, Imipenem Potentiators against Methicillin-Resistant <i>Staphylococcus aureus</i>, Produced by <i>Streptomyces canus</i> New Approaches to Drug Discovery for Combating MRSA 5,6-cis-Penems:  Broad-Spectrum Anti-Methicillin-Resistant Staphylococcus aureus β-Lactam Antibiotics In Vitro Potentiation of Carbapenems with ME1071, a Novel Metallo-β-Lactamase Inhibitor, against Metallo-β-Lactamase- Producing Pseudomonas aeruginosa Clinical Isolates Propenylamide and propenylsulfonamide cephalosporins as a novel class of anti-MRSA β-lactams New .BETA.-lactam antibiotics, carpetimycins C and D. Thiophenyl oxime-derived phosphonates as nano-molar class C beta-lactamase inhibitors reducing MIC of imipenem against Pseudomonas aeruginosa and Acinetobacter baumannii PS-8, a minor carbapenem antibiotic.